

Histone deacetylase (HDAC) Inhibitors– Pipeline Insight, 2020

<https://marketpublishers.com/r/H67C69B05271EN.html>

Date: November 2020

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: H67C69B05271EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Histone deacetylase (HDAC) Inhibitors– Pipeline Insight, 2020," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Histone deacetylase (HDAC) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Histone deacetylase (HDAC) Inhibitors Understanding

Histone deacetylase (HDAC) Inhibitors: Overview

The histone deacetylase inhibitors (HDACi) are a group of small molecules that target histone deacetylases (HDACs) by inhibiting their activity. HDACi have a long history of use in neurology and psychiatry as antiepileptics and mood stabilizers. More recently, they have been investigated as possible treatments for cancer. Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Eighteen human HDAC enzymes have been identified and classified into four groups based on their homology with yeast HDACs.

The acetylation of histones by HAT changes their charge from positive to negative, which reduces their interaction with negatively-charged DNA. This increases accessibility for the transcriptional machinery, resulting in transcriptional activation. This series of the events can be reversed by deacetylation by HDACs. Epigenetic changes caused by imbalances between HATs and HDACs can affect global transcriptional profiles.

HDACs are so-named because they were first identified as enzymes that function to remove acetyl groups from lysine residues on the N-terminal tails of histones. However, recent phylogenetic studies suggest that all four classes of HDACs preceded the evolution of histone proteins, indicating that the primary substrates of HDAC enzymes are not histone proteins but non-histone proteins.

HDACs are both directly and indirectly involved in many biological processes, including development, proliferation, differentiation, and cell death.

Histone deacetylase (HDAC) Inhibitors Emerging Drugs Chapters

This segment of the Histone deacetylase (HDAC) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Histone deacetylase (HDAC) Inhibitors Emerging Drugs

Givinostat: Italfarmaco

Givinostat is an investigational drug discovered through Italfarmaco's internal research and development efforts in collaboration with Lorenzo Puri (SanfordBurnhamPrebys Medical Research Institute, San Diego, formerly Santa Lucia Foundation, Rome) and his team, and partnerships with Telethon and Parent Project aps. It is being evaluated for safety and efficacy for the treatment of Duchenne- and Becker- Muscular Dystrophy. Givinostat inhibits histone deacetylases (HDACs). HDACs are enzymes that prevent gene translation by changing the three-dimensional folding of DNA in the cell. Studies show that Duchenne patients have higher than normal HDAC levels, which may prevent muscle regeneration, and also trigger inflammation. In the company's clinical study in

DMD boys aged seven to less than 11 years, Givinostat was observed to slow disease progression, significantly increase muscle mass and reduce the amount of fibrotic tissue. Givinostat treatment also significantly reduced muscle tissue necrosis and fatty replacement, two additional parameters related to disease progression (Bettica et al., Neuromuscular Disorder 2016).

Further product details are provided in the report.....

Histone deacetylase (HDAC) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Histone deacetylase (HDAC) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Histone deacetylase (HDAC) Inhibitors

There are approx. 50+ key companies which are developing the Histone deacetylase (HDAC) Inhibitors. The companies which have their Histone deacetylase (HDAC) Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Italfarmaco.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Histone deacetylase (HDAC) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Histone deacetylase (HDAC) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Histone deacetylase (HDAC) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Histone deacetylase (HDAC) Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Histone deacetylase (HDAC) Inhibitors R&D. The therapies under development are focused on novel approaches for Histone deacetylase (HDAC) Inhibitors.

April 2020: Onxeo announced that it had entered into agreements (“the Agreements”) with Acrotech Biopharma which extend Acrotech’s rights to belinostat, to all territories not previously covered under Onxeo’s prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms. Onxeo would receive a one-time payment of \$6.6 million from Acrotech in exchange for these rights. Belinostat is currently marketed in the U.S. under the name Beleodaq (belinostat for injection) in the second-line treatment of patients with peripheral T cell lymphoma.

Histone deacetylase (HDAC) Inhibitors Report Insights

Histone deacetylase (HDAC) Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Histone deacetylase (HDAC) Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Histone deacetylase (HDAC) Inhibitors drugs?

How many Histone deacetylase (HDAC) Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Histone deacetylase (HDAC) Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Histone deacetylase (HDAC) Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Histone deacetylase (HDAC) Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Roche

Takeda San Diego

Italfarmaco

Sulfidris

MethylGene

EpiGen Pharmaceuticals

DAC Research

Karus Therapeutics

Xynomic Pharmaceuticals

Medivir

Mirati Therapeutics

Janssen Pharmaceutica

Key Products

Research programme: histone deacetylase inhibitors

ACS 33

MG 4915

AP CANC04

DAC 0060

KAR 2581

Abexinostat

Remetinostat

Mocetinostat

Quisinostat

Contents

- Introduction
- Executive Summary
- Histone deacetylase (HDAC) Inhibitors: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Histone deacetylase (HDAC) Inhibitors – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - Histone deacetylase (HDAC) Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends
- Histone deacetylase (HDAC) Inhibitors Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Givinostat: Italfarmaco
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- Drug Name: Company Name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
 - Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Histone deacetylase (HDAC) Inhibitors Key Companies

Histone deacetylase (HDAC) Inhibitors Key Products

Histone deacetylase (HDAC) Inhibitors- Unmet Needs

Histone deacetylase (HDAC) Inhibitors- Market Drivers and Barriers

Histone deacetylase (HDAC) Inhibitors- Future Perspectives and Conclusion

Histone deacetylase (HDAC) Inhibitors Analyst Views

Histone deacetylase (HDAC) Inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Histone deacetylase (HDAC) Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Histone deacetylase (HDAC) Inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Histone deacetylase (HDAC) Inhibitors– Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/H67C69B05271EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H67C69B05271EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970